Investigational Obesity Medication Demonstrates Efficacy for Obstructive Sleep Apnea

New research in The New England Journal of Medicine indicates Eli Lilly's experimental obesity drug, retatrutide, significantly reduced breathing interruptions and other symptoms of obstructive sleep apnea (OSA). The investigational weight-loss drug showed promise in two clinical trials, and is currently undergoing phase 3 trials for obesity and related metabolic conditions. This suggests a potential new therapeutic approach for millions affected by OSA.